Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.210
+0.085 (7.56%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Quince Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Cash & Equivalents | 6.21 | 20.75 | 44.58 | 69.72 | 66.84 | Upgrade
|
| Short-Term Investments | 34.57 | 54.31 | 45.6 | 37.08 | 66.98 | Upgrade
|
| Cash & Short-Term Investments | 40.78 | 75.06 | 90.18 | 106.8 | 133.82 | Upgrade
|
| Cash Growth | -45.66% | -16.77% | -15.56% | -20.19% | 34.00% | Upgrade
|
| Other Receivables | 0.88 | 0.99 | 1 | 1.13 | - | Upgrade
|
| Receivables | 0.88 | 0.99 | 1 | 1.13 | - | Upgrade
|
| Prepaid Expenses | 0.99 | 1.17 | 1.2 | 1.48 | 1.24 | Upgrade
|
| Other Current Assets | 1.38 | 0.21 | 1.36 | 2.27 | 2.8 | Upgrade
|
| Total Current Assets | 44.04 | 77.44 | 93.75 | 111.67 | 137.86 | Upgrade
|
| Property, Plant & Equipment | 0.81 | 0.62 | 0.68 | 1.43 | 1.1 | Upgrade
|
| Long-Term Investments | 0.08 | 0.08 | 3.58 | 19.93 | 50.46 | Upgrade
|
| Goodwill | - | 17.63 | - | - | - | Upgrade
|
| Other Intangible Assets | 60.05 | 63.67 | 5.9 | - | - | Upgrade
|
| Other Long-Term Assets | 9.51 | 8.47 | - | 0.19 | 0.04 | Upgrade
|
| Total Assets | 114.48 | 167.9 | 103.91 | 133.23 | 189.47 | Upgrade
|
| Accounts Payable | 2.9 | 2.03 | 0.57 | 4.91 | 3.56 | Upgrade
|
| Accrued Expenses | 3.97 | 3.12 | 1.86 | 8.39 | 13.16 | Upgrade
|
| Current Portion of Leases | 0.1 | 0.06 | 0.45 | 0.74 | 0.24 | Upgrade
|
| Other Current Liabilities | 0.31 | 4.36 | 0.19 | 0.18 | 0.04 | Upgrade
|
| Total Current Liabilities | 7.28 | 9.57 | 3.07 | 14.22 | 17 | Upgrade
|
| Long-Term Debt | 14.32 | 13.43 | - | - | - | Upgrade
|
| Long-Term Leases | 0.39 | 0.32 | - | 0.42 | 0.21 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 4.96 | 5.3 | 0.25 | - | - | Upgrade
|
| Other Long-Term Liabilities | 57.38 | 54.19 | - | - | - | Upgrade
|
| Total Liabilities | 84.33 | 82.82 | 3.32 | 14.64 | 17.2 | Upgrade
|
| Common Stock | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | Upgrade
|
| Additional Paid-In Capital | 406.61 | 401.64 | 389.11 | 355.23 | 318.57 | Upgrade
|
| Retained Earnings | -376.47 | -319.64 | -288.26 | -236.6 | -146.65 | Upgrade
|
| Comprehensive Income & Other | -0.04 | 3.05 | -0.29 | -0.08 | 0.31 | Upgrade
|
| Total Common Equity | 30.15 | 85.08 | 100.59 | 118.59 | 172.26 | Upgrade
|
| Shareholders' Equity | 30.15 | 85.08 | 100.59 | 118.59 | 172.26 | Upgrade
|
| Total Liabilities & Equity | 114.48 | 167.9 | 103.91 | 133.23 | 189.47 | Upgrade
|
| Total Debt | 14.81 | 13.81 | 0.45 | 1.16 | 0.45 | Upgrade
|
| Net Cash (Debt) | 25.97 | 61.25 | 89.73 | 105.64 | 133.37 | Upgrade
|
| Net Cash Growth | -57.59% | -31.74% | -15.06% | -20.79% | 33.56% | Upgrade
|
| Net Cash Per Share | 0.60 | 1.64 | 2.68 | 3.55 | 4.57 | Upgrade
|
| Filing Date Shares Outstanding | 44 | 43.22 | 36.28 | 30.15 | 29.55 | Upgrade
|
| Total Common Shares Outstanding | 44 | 42.97 | 36.14 | 30.07 | 29.54 | Upgrade
|
| Working Capital | 36.76 | 67.87 | 90.68 | 97.45 | 120.87 | Upgrade
|
| Book Value Per Share | 0.69 | 1.98 | 2.78 | 3.94 | 5.83 | Upgrade
|
| Tangible Book Value | -29.9 | 3.79 | 94.69 | 118.59 | 172.26 | Upgrade
|
| Tangible Book Value Per Share | -0.68 | 0.09 | 2.62 | 3.94 | 5.83 | Upgrade
|
| Machinery | 0.89 | 0.68 | 0.43 | 0.61 | 0.46 | Upgrade
|
| Leasehold Improvements | 0.03 | 0.04 | 0.02 | 0.06 | 0.02 | Upgrade
|
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.